welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Molecular Analysis of Patients With Neuromuscular Disease
study id #: NCT00390104
condition: Limb-girdle Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy
The purpose of this study is to identify genes and proteins responsible for nerve and muscle disorders by studying genetic material from individuals with neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy but have no causative gene implicated in their disease. We feel that these patients may have new genetic changes in genes coding for important muscle proteins that we have yet to identify. Using molecular genetics to unravel the biochemical basis of these neuromuscular disorders should lead to more accurate diagnosis of these disorders and should lead to potential therapies.
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: January 2002
estimated completion: December 31, 2020
size / enrollment: 1000
We aim to identify and characterize the genetic changes responsible for the neuromuscular diseases found in our participants and their families. Our research lab has a long history of identifying novel genes responsible for various forms of neuromuscular disease including; dystrophin, the sarcoglycans, obscurin, and filamin. Each discovery has resulted in advances in our ability to develop diagnostic tests which benefit patients and their families by providing accurate diagnosis, presymptomatic and/or prenatal testing. Genotype-phenotype correlation studies have increased our understanding of the natural history of these rare disorders benefiting patients through better prognostic determinations by clinicians. Biochemical and pathological analysis of muscle biopsies in patient with known and unknown types of neuromuscular disease has led to new insights into disease pathophysiology which we hope will aid in finding treatments.
• having a clinical and/or pathological diagnosis of a muscular dystrophy
• being the first degree relative of someone with such a diagnosis
• having had a muscle biopsy if diagnosed with a neuromuscular disease
• willingness to provide a skin biopsy for research only
• not having such a diagnosis and not being related to such an individual
• not wishing to participate
• being incapable of giving consent and not having a legal guardian willing or able to do so
Givinostat in Duchenne’s Muscular Dystrophy Long-term Safety and Tolerability StudyThis is an open label, long-term safety,...
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyStudy to characterize the single-state a...
Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular DystrophyThis is a pilot clinical trial to assess...
2D Strain Evaluation: Children With Duchenne Muscular Dystrophy Versus Healthy ChildrenCompare systolic function of left ventri...
Assessment of Cardiopulmonary Function in Duchenne Muscular DystrophyThis study seeks to develop and validate...
Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic TomographyThis pilot study aims to assess subcellu...
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortThis is an open label, long-term extensi...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Katy Eichinger, PhD, DPTKaty Eichinger is an assistant professor...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...